Akahoshi Y,Arai Y,Nishiwaki S,Mizuta S,Marumo A,Uchida N,Kanda Y,Sakai H,Takada S,Fukuda T,Fujisawa S,Ashida T,Tanaka J,Atsuta Y Kako S:Minimal residual disease (MRD) positivity at allogeneic hematopoietic cell transplantation,not the quantity of MRD,is a risk factor for relapse of Philadelphia chromosome-positive acute lymphoblastic leukemia. Int J Hematol,113(6):832-839,2021.
Akahoshi Y,Arai Y,Nishiwaki S,Tachibana T,Shinohara A,Doki N,Uchida N,Tanaka M,Kanda Y,Shiratori S,Ozawa Y,Shono K,Katayama Y,Tanaka J,Fukuda T,Atsuta Y,Kako S:Newly proposed threshold and validation of white blood cell count at diagnosis for Philadelphia chromosome-positive acute lymphoblastic leukemia: risk assessment of relapse in patients with negative minimal residual disease at transplantation-a report from the Adult Acute Lymphoblastic Leukemia Working Group of the JSTCT. Bone Marrow Transplant,56(11):2842-2848,2021.
Akahoshi Y,Kimura SI,Inamoto Y,Seo S,Muranushi H,Shimizu H,Ozawa Y,Tanaka M,Uchida N,Kanda Y,Katayama Y,Shiratori S,Ota S,Matsuoka KI,Onizuka M,Fukuda T,Atsuta Y,Murata M,Terakura S,Nakasone H:Effect of Cytomegalovirus Reactivation With or Without Acute Graft-Versus-Host Disease on the Risk of Nonrelapse Mortality.Clin Infect Dis,2;73(3):e620-e628,2021.
Akimoto M,Sakurai A,Nishiyama-Fujita Y,Ito C,Aisa Y,Nakazato T:The prognostic value of the Fibrinogen-Albumin Ratio Index in patients with myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes treated with azacitidine.Ann Hematol,100(4):953-957,2021.
Akiyama N,Okamura T,Yoshida M,Kimura SI,Yano S,Yoshida I,Kusaba H,Takahashi K,Fujita H,Fukushima K,Iwasaki H,Tamura K,Saeki T,Takamatsu Y,Zenda S:A questionnaire survey on evaluation for penetration and compliance of the Japanese Guideline on Febrile Neutropenia among hematology-oncology physicians and surgeons. Support Care Cancer,29(11):6831-6839,2021.
Ban T,Kikuchi M,Sato GR,Manabe A,Tagata N,Harita K,Nishiyama A,Nishimura K,Yoshimi R,Kirino Y,Yanai H,Matsumoto Y,Suzuki S,Hihara H,Ito M,Tsukahara K,Yoshimatsu K,Yamamoto T,Taniguchi T,Nakajima H,Ito S,Tamura T:Genetic and chemical inhibition of IRF5 suppresses pre-existing mouse lupus-like disease. Nat Commun,12(1):4379,2021.
Fuji S,Hakoda A,Kanda J,Murata M,Terakura S,Inamoto Y,Uchida N,Toya T,Eto T,Nakamae H,Ikegame K,Tanaka M,Kawakita T,Kondo T,Miyamoto T,Fukuda T,Ichinohe T,Kimura T,Atsuta Y,Shintani A,Morishima S:Impact of HLA disparity on the risk of overall mortality in patients with grade II-IV acute GVHD on behalf of the HLA Working Group of Japan Society for Hematopoietic Cell Transplantation. Bone Marrow Transplant,56(12):2990-2996,2021.
Fujimaki K,Hibino Y,Kishimoto K,Watanabe S,Koyama S,Ando T,Kanamori H,Nakajima N:Successful treatment with lenalidomide for relapsed adult T-cell leukemia/lymphoma after cord blood cell transplantation.Blood Cell Therapy,4:44-47,2021.
Isobe M,Konuma T,Masuko M,Uchida N,Miyakoshi S,Sugio Y,Yoshida S,Tanaka M,Matsuhashi Y,Hattori N,Onizuka M,Aotsuka N,Kouzai Y,Wake A,Kimura T,Ichinohe T,Atsuta Y,Yanada M:Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation.Single cord blood transplantation for acute myeloid leukemia patients aged 60 years or older: a retrospective study in Japan. Ann Hematol,100(7):1849-1861,2021.
Ito A,Nakano N,Tanaka T,Fuji S,Makiyama J,Inoue Y,Choi I,Nakamae H,Nagafuji K,Takase K,Machida S,Takahashi T,Sawayama Y,Kamimura T,Kato K,Kawakita T,Ogata M,Sakai R,Shiratori S,Uchimaru K,Inamoto Y,Utsunomiya A,Fukuda T:Improved survival of patients with aggressive ATL by increased use of allo-HCT: a prospective observational study.Blood Adv,26:5(20):4156-4166,2021.
Izutsu K,Ando K,Nishikori M,Shibayama H,Teshima T,Kuroda J,Kato K,Imaizumi Y,Nosaka K,Sakai R,Hojo S,Nakanishi T,Rai S:Phase II study of tazemetostat for relapsed or refractory B-cell non-Hodgkin lymphoma with EZH2 mutation in Japa. Cancer Sci,112(9):3627-3635,2021.
Kimura SI,Tamaki M,Okinaka K,Seo S,Uchida N,Igarashi A,Ozawa Y,Ikegame K,Eto T,Tanaka M,Shiratori S,Nakamae H,Sawa M,Kawakita T,Onizuka M,Fukuda T,Atsuta Y,Kanda Y,Nakasone H:Cytomegalovirus reactivation is associated with an increased risk of late-onset invasive aspergillosis independently of grade II-IV acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation: JSTCT Transplant Complications Working Group. Ann Hematol,100(12):3029-3038,2021.
Konuma T,Kanda J,Kuwatsuka Y,Yanada M,Kondo T,Hirabayashi S,Kako S,Akahoshi Y,Uchida N,Doki N,Ozawa Y,Tanaka M,Eto T,Sawa M,Yoshioka S,Kimura T,Kanda Y,Fukuda T,Atsuta Y,Kimura F:Differential Effect of Graft-versus-Host Disease on Survival in Acute Leukemia according to Donor Type. Clin Cancer Res,27(17):4825-4835,2021.
Konuma T,Kondo T,Masuko M,Shimizu H,Shiratori S,Fukuda T,Kato J,Sawa M,Ozawa Y,Ota S,Uchida N,Kanda Y,Kako S,Fujisawa S,Fukushima K,Ichinohe T,Atsuta Y,Yanada M:Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation: Prognostic value of measurable residual disease at allogeneic transplantation for adults with core binding factor acute myeloid leukemia in complete remission. Bone Marrow Transplant,56(11):2779-2787,2021.
Kunimoto H,Nakajima H:TET2: A cornerstone in normal and malignant hematopoiesis.Cancer Sci,112(1):31-40,2021.
Kurosawa S,Kaito S,Uchida N,Fukuda T,Doki N,Mori T,Hasegawa Y,Takada S,Sakaida E,Tanaka M,Ikegame K,Kanda J,Atsuta Y,Kako S:Allogeneic hematopoietic stem cell transplantation for adult patients with B-cell acute lymphoblastic leukemia with high hyperdiploidy: a retrospective nationwide study.Leuk Lymphoma,62(10):2514-2520,2021.
Kurosawa S,Yamaguchi T,Mori A,Matsuura T,Mori T,Tanaka M,Kondo T,Umemoto Y,Goto H,Yoshioka S,Machida S,Sato T,Katayama Y,Kato S,Shono K,Mizuno I,Fujiwara SI,Kohno A,Takahashi M,Fukuda T:Resignation and return to work in patients receiving allogeneic hematopoietic cell transplantation close up. J Cancer Surviv,2021.
Mizuno S,Takami A,Kawamura K,Arai Y,Kondo T,Kawata T,Uchida N,Marumo A,Fukuda T,Tanaka M,Ozawa Y,Yoshida S,Ota S,Takada S,Sawa M,Onizuka M,Kanda Y,Ichinohe T,Atsuta Y,Yanada M:Allogeneic Hematopoietic Cell Transplantation for Adolescent and Young Adult Patients with Acute Myeloid Leukemia. Transplant Cell Ther,27(4):314.e1-314.e10,2021.
Mori T,Saburi M,Hagihara M,Mori M,Yamazaki R,Kato J:Long-term remission of cryopyrin-associated periodic syndrome after allogeneic haematopoietic stem cell transplantation. Ann Rheum Dis,80(4):542-543,2021.
Morishima S,Fukuda T,Doki N,Mori T,Onizuka M,Kawakita T,Kato C,Ozawa Y,Tanaka M,Kurokawa M,Kamimura T,Inoue M,Tanaka J,Ichinohe T,Atsuta Y,Morishima Y:HLA Working Group of the Japan Society for Hematopoietic Cell Transplantation. Individual HLAs influence immunological events in allogeneic stem cell transplantation from HLA-identical sibling donors. Bone Marrow Transplant,56(3):646-654,2021.
Nakamura M,Arai Y,Hirabayashi S,Kondo T,Doki N,Uchida N,Fukuda T,Ozawa Y,Tanaka M,Sawa M,Katayama Y,Kanda Y,Shiratori S,Nakamae H,Yoshioka S,Onizuka M,Ichinohe T,Atsuta Y,Kako S:Residual disease is a strong prognostic marker in patients with acute lymphoblastic leukaemia with chemotherapy-refractory or relapsed disease prior to allogeneic stem cell transplantation.Br J Haematol,194(2):403-413,2021.
Nakazato T,Hagihara M,Sahara N,Tamai Y,Ishii R,Tamaki S,Wake A,Tajika K,Sakai R,Kobayashi T,Hua J,Inoue M,Aisa Y,Fujisawa S,Miyazaki K,Irie S,Tanaka E,Higashihara M:Phase II clinical trial of personalized VCD-VTD sequential therapy using the Vulnerable Elders Survey-13 (VES-13) for transplant-ineligible patients with newly diagnosed multiple myeloma.Ann Hematol,100(11):2745-2754,2021.
Nishiwaki S,Akahoshi Y,Mizuta S,Shinohara A,Hirabayashi S,Noguchi Y,Fukuda T,Uchida N,Tanaka M,Onizuka M,Ozawa Y,Ota S,Shiratori S,Onishi Y,Kanda Y,Sawa M,Tanaka J,Atsuta Y,Kako S:Measurable residual disease affects allogeneic hematopoietic cell transplantation in Ph+ ALL during both CR1 and CR2.Blood Adv,5(2):584-592,2021.
Nukui J,Takahashi H,Tokunaga M,Suzuki T,Suzuki M,Yokose T,Nakamura N,Sakai R,Nakajima H:Successful treatment with brentuximab vedotine for a patient with very late relapse of limited stage classic Hodgkin lymphoma.Int Cancer Conf J,15:11(1):27-30,2021.
Numata A,Sakai R,Arakaki H,Ishiyama Y,Koyama M,Takasaki H,Suzuki M,Yokose T,Yamada T,Yasui K,Yoshida T,Miyashita K,Fujisawa S,Nakamura N,Nakajima H: Simultaneous Malignancy of Primary Splenic Angiosarcoma and Low Grade B-cell Lymphoma.Hematology and Oncology:Current Research,2021.
Sakamoto Y,Isono H,Enoki Y,Taguchi K,Miyazaki T,Kunimoto H,Koike H,Hagihara M,Matsumoto K,Nakajima H,Sahashi Y,Matsumoto K:Population Pharmacokinetic Analysis and Dosing Optimization of Prophylactic Fluconazole in Japanese Patients with Hematological Malignancy.J Fungi (Basel),16(7):975,2021.
Shimomura Y,Hara M,Hirabayashi S,Kondo T,Mizuno S,Uchida N,Mukae J,Kawakita T,Fukuda T,Kanda Y,Ota S,Ozawa Y,Eto T,Maruyama Y,Tanaka M,Nakano N,Kimura T,Ichinohe T,Atsuta Y,Yanada M:Comparison of fludarabine,a myeloablative dose of busulfan,and melphalan vs conventional myeloablative conditioning regimen in patients with relapse and refractory acute myeloid leukemia in non-remission status. Bone Marrow Transplant,56(9):2302-2304,2021.
Shiratori S,Sugita J,Ota S,Kasahara S,Ishikawa J,Tachibana T,Hayashi Y,Yoshimoto G,Eto T,Iwasaki H,Harada M,Matsuo K,Teshima T:Japan Study Group for Cell Therapy and Transplantation (JSCT). Low-dose anti-thymocyte globulin for GVHD prophylaxis in HLA-matched allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant,56(1):129-136,2021.
Takahashi H,Sakai R,Sakuma T,Matsumura A,Miyashita K,Ishii Y,Nakajima Y,Numata A,Hattori Y,Miyazaki T,Hashimoto C,Koharazawa H,Takemura S,Taguchi J,Fujimaki K,Fujita H,Nakajima H:Comparison of Clinical Features Between Primary and Secondary Breast Diffuse Large B Cell Lymphoma: A Yokohama Cooperative Study Group for Hematology Multicenter Retrospective Study. Indian J Hematol Blood Transfus,37(1):60-66,2021.
Tachibana T,Kanda J,Ishizaki T,Najima Y,Tanaka M,Doki N,Fujiwara SI,Kimura SI,Onizuka M,Takahashi S,Saito T,Mori T,Fujisawa S,Sakaida E,Miyazaki T,Aotsuka N,Gotoh M,Watanabe R,Shono K,Usuki K,Tsukada N,Kanamori H,Kanda Y,Okamoto S: Kanto Study Group for Cell Therapy (KSGCT): Clinical Benefits of Preconditioning Intervention in Patients with Relapsed or Refractory Acute Myelogenous Leukemia Who Underwent Allogeneic Hematopoietic Cell Transplantation: A Kanto Study of Group for Cell Therapy Multicenter Analysis. Transplant Cell Ther,27(1):70.e1-70.e8,2021.
Tachibana T,Kanda J,Ishizaki T,Najima Y,Tanaka M,Doki N,Fujiwara SI,Kimura SI,Onizuka M,Takahashi S,Saito T,Mori T,Fujisawa S,Sakaida E,Miyazaki T,Aotsuka N,Gotoh M,Watanabe R,Shono K,Kanamori H,Kanda Y,Okamoto S:Kanto Study Group for Cell Therapy (KSGCT): Pre-conditioning intervention in patients with relapsed or refractory acute lymphoblastic leukemia who underwent allogeneic hematopoietic cell transplantation: a KSGCT multicenter retrospective analysis. Ann Hematol,100(11):2763-2771,2021.
Teshigawara-Tanabe H,Hagihara M,Matsumura A,Takahashi H,Nakajima Y,Miyazaki T,Kamijo A,Yamazaki E,Fujimaki K,Matsumoto K,Nakajima H:Passenger lymphocyte syndrome after ABO-incompatible allogeneic hematopoietic stem cell transplantation; dynamics of ABO allo-antibody and blood type conversion. Hematology,26(1):835-839,2021.
Yamayoshi S,Yasuhara A,Ito M,Akasaka O,Nakamura M,Nakachi I,Koga M,Mitamura K,Yagi K,Maeda K,Kato H,Nojima M,Pattinson D,Ogura T,Baba R,Fujita K,Nagai H,Yamamoto S,Saito M,Adachi E,Ochi J,Hattori SI,Suzuki T,Miyazato Y,Chiba S,Okuda M,Murakami J,Hamabata T,Iwatsuki-Horimoto K,Nakajima H,Mitsuya H,Omagari N,Sugaya N,Yotsuyanagi H,Kawaoka Y:Antibody titers against SARS-CoV-2 decline,but do not disappear for several months.EClinicalMedicine,32:100734,2021.
Yanada M,Konuma T,Mizuno S,Saburi M,Shinohara A,Tanaka M,Marumo A,Sawa M,Uchida N,Ozawa Y,Onizuka M,Yoshioka S,Nakamae H,Kondo T,Kimura T,Kanda J,Fukuda T,Atsuta Y,Nakasone H,Yano S:Predicting non-relapse mortality following allogeneic hematopoietic cell transplantation during first remission of acute myeloid leukemia. Bone Marrow Transplant,56(2):387-394,2021.
Yanada M,Konuma T,Yamasaki S,Harada K,Iwasaki M,Kobayashi A,Nishijima A,Tanaka M,Uchida N,Nakamae H,Fukuda T,Onizuka M,Ozawa Y,Sawa M,Katayama Y,Yoshioka S,Kimura T,Ichinohe T,Atsuta Y,Kanda J,Yano S:Allogeneic Hematopoietic Cell Transplantation from Alternative Donors in Acute Myelogenous Leukemia: A Comparative Analysis. Transplant Cell Ther,27(12):1005. e1-1005.e8,2021.
Yanada M,Konuma T,Yamasaki S,Kondo T,Fukuda T,Shingai N,Sawa M,Ozawa Y,Tanaka M,Uchida N,Nakamae H,Katayama Y,Matsuoka KI,Kimura T,Kanda Y,Ichinohe T,Atsuta Y,Yano S:Relapse of acute myeloid leukemia after allogeneic hematopoietic cell transplantation: clinical features and outcomes. Bone Marrow Transplant,56(5):1126-1133,2021.
Yanada M,Konuma T,Yamasaki S,Mizuno S,Hirabayashi S,Nishiwaki S,Uchida N,Doki N,Tanaka M,Ozawa Y,Sawa M,Eto T,Kawakita T,Ota S,Fukuda T,Onizuka M,Kimura T,Atsuta Y,Kako S,Yano S:The differential effect of disease status at allogeneic hematopoietic cell transplantation on outcomes in acute myeloid and lymphoblastic leukemia. Ann Hematol,100(12):3017-3027,2021.
Yanada M,Konuma T,Yamasaki S,Kondo T,Fukuda T,Shingai N,Sawa M,Ozawa Y,Tanaka M,Uchida N,Nakamae H,Katayama Y,Matsuoka KI,Kimura T,Kanda Y,Ichinohe T,Atsuta Y,Yano S:Relapse of acute myeloid leukemia after allogeneic hematopoietic cell transplantation: clinical features and outcomes. Bone Marrow Transplant,56(5):126-1133,2021.
Yanada M,Mizuno S,Yamasaki S,Harada K,Konuma T,Tamaki H,Shingai N,Uchida N,Ozawa Y,Tanaka M,Onizuka M,Sawa M,Nakamae H,Shiratori S,Matsuoka KI,Eto T,Kawakita T,Maruyama Y,Ichinohe T,Kanda Y,Atsuta Y,Aoki J,Yano S:Difference in outcomes following allogeneic hematopoietic cell transplantation for patients with acute myeloid leukemia and myelodysplastic syndromes. Leuk Lymphoma,62(14):3411-3419,2021.
Yamauchi N,Maruyama D,Choi I,Atsuta Y,Sakai R,Miyashita K,Moriuchi Y,Tsujimura H,Kubota N,Yamamoto G,Igarashi T,Izutsu K,Yoshida S,Kojima K,Uchida T,Inoue Y,Tsukamoto N,Ohtsuka E,Suzuki S,Inaguma Y,Ichikawa S,Gomyo H,Ushijima Y,Nosaka K,Kurata M,Tanaka Y,Ueda R,Mizokami M,Kusumoto S:Prophylactic antiviral therapy for hepatitis B virus surface antigen-positive patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy．Cancer Sci,112(5):1943-1954,2021.
Yokoyama H,Hirayama M,Takahashi Y,Uchida N,Tanaka M,Onizuka M,Ozawa Y,Onai D,Katsuoka Y,Wake A,Sawa M,Kobayashi H,Maruyama Y,Ozeki K,Kimura T,Kanda J,Fukuda T,Atsuta Y,Terakura S,Morishima S:Altered effect of killer immunoglobulin-like receptor-ligand mismatch by graft versus host disease prophylaxis in cord blood transplantation. Bone Marrow Transplant,56(12):3059-3067,2021.
